key: cord-1026398-hnfj4es8
authors: Bivins, Aaron; Bibby, Kyle
title: Wastewater Surveillance during Mass COVID-19 Vaccination on a College Campus
date: 2021-08-23
journal: Environ Sci Technol Lett
DOI: 10.1021/acs.estlett.1c00519
sha: ebd82f89731104f52be3106af1ddf9bc928f7d39
doc_id: 1026398
cord_uid: hnfj4es8

[Image: see text] The suitability of wastewater monitoring following widespread vaccination against COVID-19 remains uncertain. SARS-CoV-2 RNA levels were monitored in wastewater solids during a university mass vaccination campaign in which >90% of the 12280 students were fully vaccinated (Pfizer-BioNTech, BNT162b2). SARS-CoV-2 RNA levels in wastewater solids correlated with the 7-day average of COVID-19 cases when lagged by 1–3 days (ρ = 0.51–0.55; p = 0.023–0.039). During and after the second vaccine dose, SARS-CoV-2 RNA was not detected in wastewater solids on 19 of 21 days (12 consecutive days of nondetection at the end of the semester), a significant decrease (p = 0.027) in positivity rate. A large influx of outside visitors (move out and commencement) led to an immediate increase in wastewater SARS-CoV-2 RNA positivity (seven detections over seven days). Wastewater solids offer a sensitive matrix for environmental surveillance of COVID-19 at the subsewershed level (50% probability of RNA detection with two cases) both during and after mass vaccination. Mass vaccination was coincident with decreased shedding of SARS-CoV-2 RNA into wastewater. This suggests the absence of a large population of shedding infections, symptomatic or not, following mass vaccination among a university campus population.

Whether they show symptoms of coronavirus disease 2019 (COVID-19), 1,2 people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shed the virus and its genetic material in their body fluids. 3−5 Because these body fluids are frequently collected via domestic wastewater, wastewater-based epidemiology has emerged as a useful method for monitoring COVID-19 trends within communities. 6 ,7 SARS-CoV-2 RNA levels in primary influent 8, 9 and primary solids 10, 11 have been observed to correlate with COVID-19 cases and positivity rate. When clinical testing is limited or delayed, wastewater signals may even precede COVID-19 trends as estimated by clinical surveillance. 12−14 More recently, SARS-CoV-2 RNA measurements in wastewater have been used to estimate the reproductive number during COVID-19 epidemics 15 with some finding wastewater outperforms clinical testing to estimate COVID-19 incidence during periods of "high [clinical] positivity" (>26%). 16 Importantly, the effectiveness of vaccines, including the BNT162b2 mRNA vaccine, against shedding of SARS-CoV-2 RNA remains uncertain, 17, 18 as is the resulting effect on wastewater monitoring strategies and design.

Enveloped viruses, including SARS-CoV-2, appear to partition preferably to the solids fraction in wastewater. 19−21 Evidence from several studies suggests that wastewater solids could offer a methodologically convenient (e.g., no need for concentration) and sensitive matrix for wastewater surveillance of SARS-CoV-2. SARS-CoV-2 RNA concentrations in primary sewage sludge tracked increases in COVID-19 cases at the population level and led case trends by up to 2 days based on specimen collection date 11 and at another wastewater surveillance site led hospitalizations by up to 4 days. 12 Both SARS-CoV-2 RNA concentrations and concentrations normalized for fecal strength using enumerations of pepper mild mottle virus (PMMoV), a fecal indicator, in settled solids demonstrated positive association with new COVID-19 cases during both the rising and falling of the epidemic curve. 20 This correlation was also observed at a surveillance site in Ottawa, ON, even during a period characterized by decreasing and low incidence. 10 During a study including wastewater from approximately 3% of the United States population, SARS-CoV-2 RNA concentrations normalized by PMMoV in primary solids were predictive of incident COVID-19 cases. 22 Wastewater surveillance has been leveraged to manage COVID-19 at universities across the United States, 23, 24 including the University of Notre Dame (ND). 25 Previously, SARS-CoV-2 RNA in campus wastewater was used to infer the RNA shedding distribution following infection. 26 More recently, the raw wastewater solids fraction collected from individual residence halls was used to monitor SARS-CoV-2 infections among building-level populations. 27 The purpose of the wastewater surveillance described herein was to examine the SARS-CoV-2 RNA signal in wastewater during mass vaccination. We hypothesized that a large and rapid increase in vaccination coverage on the ND campus would be associated with not only a decrease in COVID-19 cases but also a decrease in SARS-CoV-2 RNA in the wastewater solids.

Raw Wastewater Composite Samples. Wastewater produced on the ND campus was sampled using an Avalanche multibottle, multifunction sampler (Teledyne ISCO, Lincoln, NE) from April 8, 2021, to May 26, 2021 . Each day, a 24 h time-based composite sample was prepared by sampling 50 mL of raw wastewater every hour from the metered outfall for the entire campus (total sample volume of 1200 mL per day split between two sample bottles). All wastewater produced on the ND campus travels through this manhole. Daily composite samples were stored at 4°C onboard the Avalanche sampler or in the laboratory until they were processed within 48 h of collection from the sampler.

Separation of Wastewater Solids. The composite raw wastewater sample from each day was well mixed by vigorous shaking, and then a single 25 mL subsample was pipetted from each of two sample bottles per day into a 50 mL centrifuge tube. The mass of each centrifuge tube was recorded prior to addition of the sample. Each 50 mL wastewater subsample was then centrifuged at 10000g for 10 min at 4°C. The resulting supernatant was decanted, and the mass of the remaining pelleted material recorded. The pellet was then resuspended using 1 mL of a PBS/Tween 20 solution (10 mM sodium phosphate, 0.15 M NaCl, and 0.05% Tween 20) by pipet mixing and vortexing, and 1 mL of the resulting mixture was transferred into a 2 mL PowerBead tube containing 0.1 mm glass beads (Qiagen, Hilden, Germany). Following the transfer of the resuspended solids, each PowerBead tube was also seeded with 5 μL of bovine respiratory syncytial virus (BRSV) (an extraction control) in the form of an intranasal cattle vaccine (Inforce 3, Zoetis, Parsippany-Troy Hills, NJ) at a titer of 21800 ± 4560 GC/μL as determined by direct extraction of seven 500 μL aliquots of seeded wastewater measured in triplicate 28 over the 49-day sampling period. Seeded wastewater solids samples were stored at −80°C until they were extracted. A sample blank consisting of 1 mL of the PBS/ Tween 20 solution seeded with BRSV was prepared with each wastewater sample batch to estimate recovery. DNA and RNA were extracted from the resuspended wastewater solids using the AllPrep PowerViral DNA/RNA kit (Qiagen) per the procedure detailed in the Supporting Information.

RT-ddPCR. Purified nucleic acids from each wastewater solids sample were assayed by RT-ddPCR for RNA targets using the Bio-Rad (Hercules, CA) QX200 Droplet Digital PCR System per the procedures detailed in the Supporting Information. SARS-CoV-2 RNA was measured in each sample using the CDC N1 assay 29 performed in triplicate reactions using premixed primers and probes from the 2019-nCoV RUO Kit (10006713, IDT, Coralville, IA). BRSV was measured in a single reaction per sample using a previously reported RT-ddPCR assay. 28 PMMoV, a proposed human fecal indicator virus with an RNA genome, 30 was measured in a single RT-ddPCR per sample as an endogenous control using an assay targeting the replicase protein. 31, 32 Lastly, inhibition was independently assessed in each sample using heat-extracted (75°C for 3 min per the manufacturer's protocol) hepatitis G (Hep G) Armored RNA (42024, Asuragen, Austin, TX) seeded into each RT-ddPCR mixture (1491 ± 48 GC/μL). All primers and probes were synthesized by IDT, with the exception of the PMMoV probe, which uses a minor groove binder (MGB) and was synthesized by Applied Biosystems (Foster City, CA). RT-ddPCR details, primer and probe sequences, working concentrations, and thermal cycling conditions as executed on a C1000 Touch Thermal Cycler (Bio-Rad) are summarized in the Supporting Information and  Table S1 .

The mean RNA copy number and 95% confidence intervals for each RT-ddPCR were estimated using Poisson statistics with manual thresholding performed in QuantaSoft version 1.7.4 (Bio-Rad) such that negative controls, including sample blanks, were negative for the relevant target. For SARS-CoV-2 RNA detections, the mean and 95% confidence interval (total error as estimated by QuantaSoft) were reported. For nondetections, the 95% LOD accounting for the extraction input mass was reported. For comparison with clinical COVID-19 data, SARS-CoV-2 data were used in three forms. The first was the N1 copy number per gram of wet mass solids from each sample (calculated per eq S1 as shown in Table S3 ). The second was the N1 copy number per gram of wet mass solids with recovery correction (the result from eq S1 divided by the BRSV recovery). The third was the N1 copy number per gram of wet mass solids normalized by the PMMoV RNA copy number per gram of wet mass solids. The error in the PMMoV-normalized calculation was propagated by adding the relative error of both the N1 copy number and the PMMoV RNA copy number as estimated by the 95% confidence interval from QuantaSoft. 20 COVID-19 Clinical Monitoring. During the period leading up to the mass vaccination campaign, COVID-19 safety protocols, including universal masking indoors and outdoors, physical distancing, daily health checks, and mandatory weekly clinical surveillance testing, were in place at ND. COVID-19 surveillance testing methods included saliva-based PCR testing for asymptomatic and nasal swab PCR and rapid antigen tests for symptomatic testing. COVID-19 cases identified by clinical testing entered off-campus isolation for at least 10 days and were not contributing to the campus wastewater stream being monitored. All clinical testing data were made public daily on the COVID-19 dashboard (https://here.nd.edu/ourapproach/dashboard/spring-2021-data/). All COVID-19 data reported in this study were extracted from the publicly available dashboard. The use of anonymous testing data has been approved by the University of Notre Dame Institutional Review Board (21-04-6586).

COVID-19 Mass Vaccination Campaign. On March 25, 2021, the Indiana Department of Health notified ND that it would be allowed to administer an on-campus vaccination campaign to all students, faculty, and staff. The campaign would administer the required two doses of the Pfizer-BioNTech vaccine in a two-phase administration. The first dose period of the vaccination campaign began on April 8, 2021, and lasted through April 15, by which time 90% of the 12280 undergraduate and professional students had received their first dose or were completely vaccinated. As of April 27, 2021, 60% of faculty and 41% of staff (estimated total population of 6358) had also received their first dose or been 33 Correlations between wastewater data and COVID-19 case metrics were assessed via the Spearman correlation coefficient 34 (ρ). The wastewater positivity rate or clinical positivity rate was calculated as the number of positive tests divided by the total number of tests over an interval of time (for wastewater testing) or on a daily basis (for clinical testing). Differences in the wastewater solids positivity rate for SARS-CoV-2 RNA were assessed using Fisher's exact test. 35 All statistical analyses and graphs were prepared using GraphPad (LaJolla, CA) Prism version 9.0.0. All raw RT-ddPCR data have been uploaded to a publicly available repository (https:// osf.io/t6hc9/) with an associated doi of 10.17605/OSF.IO/ T6HC9, and a Minimum Information for Publication of Quantitative Digital PCR Experiments (dMIQE) 36 checklist has been completed in Table S2 .

Wastewater Analytical Performance. A total of 49 daily wastewater solids samples were collected from the ND sewage system from April 8 to May 26 with an average wet mass of 1.27 g (range of 0.69−2.71 g). The mean 95% sample LOD was 20.2 N1 copies per gram of wet mass collected. The mean extraction efficiency as estimated by BRSV was 3.6% [95% confidence interval (CI) of 2.5−4.7 ( Figure S1 )], which is higher than previously reported for whole process BRSV recovery during concentration with electronegative membranes, 28 but lower than bovine coronavirus recoveries from wastewater solids. 22 The lower recovery could be caused by the addition of 1 mL of resuspended solids (in an effort to increase analytical sensitivity) into an extraction kit with a recommended loading of 200 μL. However, there is little consensus on the appropriate use of endogenous and exogenous controls for wastewater surveillance. 37 Differences in log 10 Hep G RNA copy numbers ( Figure S2 ) between samples and controls ranged from 0.002 to 0.193 with a mean of 0.040 ± 0.037, suggesting little inhibition. Examples of positive and negative results for each assay are listed in Table S4 , and digital PCR performance parameters (partition volume, partition number, and copies per partition) are summarized in Table S5 . Across all experiments, no-template controls and sample blanks were negative for all RT-ddPCR targets.

COVID-19 Trends by Clinical Testing. The incidence of COVID-19 cases decreased throughout the entire study period (Figure 1 ). During the first 21-day vaccine dose period (April 8−28), an average of 1595 COVID-19 clinical tests were performed each day. The incidence of COVID-19 decreased from a rolling 7-day average of 9.4 cases per day on April 8 to 1.9 cases per day by April 28. During the second dose administration (April 29 to May 19), the daily incidence was ≤2 cases with the last case of COVID-19 detected by clinical surveillance on May 7, 2021. The rolling 7-day average of incident COVID-19 cases reached 0 on May 14, 2021, and remained so for the rest of the study. It should be noted that the average number of COVID-19 tests administered decreased to 203 per day after May 7 because fully vaccinated Correlation between Wastewater Solids and Clinical Data. Prior to the end of the semester, SARS-CoV-2 N1 copies per gram of wastewater solids were positively correlated with the 7-day average COVID-19 cases when wastewater data were lagged 1 day (ρ = 0.51; p = 0.038), 2 days (ρ = 0.55; p = 0.023), and 3 days (ρ = 0.51; p = 0.039) (data pairings illustrated in Table S6 ). N1 copies per gram of wastewater solids were also moderately correlated with same-day COVID-19 cases (ρ = 0.47; p = 0.057), although the correlation was not statistically significant. Recovery correction ( Figure S5 ) produced correlations that were frequently negative or weakly positive compared to COVID-19 cases. As opposed to previous studies, normalization by PMMoV ( Figure S7 ) also produced correlations that were frequently weak and statistically insignificant. During the previous studies, measurements were made using wastewater solids at treatment plants, whereas in the study presented here, samples were collected at the subsewershed level. The difference in results could be attributable to greater variation at the subsewer level or the use of composite sampling rather than the inherent compositing associated with primary treatment. With the exception of the 7day average COVID-19 cases and N1 copies per gram, lagging or leading wastewater data relative to case data did not improve correlation. No statistically significant positive correlation was observed between COVID-19 clinical positivity and N1 copies per gram ( Figure S4 ), with recovery correction ( Figure S6 ), or with PMMoV normalization ( Figure S8 ).

Presence of SARS-CoV-2 RNA in Wastewater Solids during Vaccination. The wastewater signal during the vaccination campaign was assessed via its positivity for SARS-CoV-2 RNA. As shown in Figure 1 , during the first dose and intervening period (April 8−28), SARS-CoV-2 RNA was detected in wastewater solids on 13 of 21 days, yielding a positivity rate of 62%. From the start of the second dose period (April 29) until the end of the semester (May 19), SARS-CoV-2 RNA was detected in wastewater solids on only 5 of 21 days for a positivity of 24%, a significant decrease in positivity (p = 0.028). In the same period, significant differences in PMMoV (p = 0.230), solids wet mass (p = 0.386), recovery (p = 0.079), and wastewater flow (p = 0.055) were not observed ( Figures  S9 and S10) . From the last clinically diagnosed case of COVID-19 on May 7 until May 18, wastewater solids were negative for SARS-CoV-2 RNA for 12 straight days.

After the end of the semester, there was an influx of visitors to the ND campus associated with student move out and commencement weekend. As shown in Figure 1 , during and immediately after this weekend, measured SARS-CoV-2 RNA levels in wastewater solids increased to the highest levels observed during the study period (951 N1 copies/g on Monday, May 24). SARS-CoV-2 RNA was detected in wastewater solids each of the 7 days during this period, although the wastewater flow (p < 0.001) and recovery efficiency (p = 0.0003) were significantly different from those of the previous 21 days, making direct comparisons difficult. Concurrently, there were no COVID-19 cases detected among students remaining on campus that were still subject to testing (unvaccinated).

Wastewater Solids for Sensitive COVID-19 Surveillance in the Subsewershed. Previous studies have established the usefulness of wastewater solids for monitoring COVID-19 cases within communities. 10, 11, 20, 22 However, each of these studies utilized primary solids collected from the settler at a wastewater treatment plant. In the work presented here, wastewater solids were taken from 24 h composite samples collected from a manhole at the subsewershed level. Despite low levels of SARS-CoV-2 RNA (<200 copies per gram of solids), and many nondetections, N1 copy numbers by RT-ddPCR demonstrated moderate correlation with same-day COVID-19 cases and rolling 7-day COVID-19 cases when lagged by 1−3 days even during a period of extremely low COVID-19 incidence. Over the study period, the wastewater solids positivity rate was 50% across all days when two incident COVID-19 cases were detected, 43% across all days when a single COVID-19 case was detected, and >95% across all days when at least 11.4 COVID-19 cases were detected among the population of 12280 students. For each of these estimates, it is possible that the actual number of COVID-19 cases was higher due to false negatives in clinical testing or cases that were otherwise not ascertained. Despite this, wastewater solids appear to offer a sensitive matrix for environmental surveillance of COVID-19 at the subsewershed level, even during and after mass vaccination.

SARS-CoV-2 RNA Shedding following Vaccination. The effectiveness of mRNA vaccine BNT162b2 against symptomatic coronavirus disease 2019 (COVID-19) has been established through rigorous clinical trial 17 and cohort studies of various subpopulations. 38−43 Observations by clinical testing among the student population at ND corroborate the effectiveness of the vaccine against COVID-19 with incident cases decreasing throughout the vaccination campaign. The last COVID-19 case among students was detected on the day after the end of the second dose administration. There were no COVID-19 cases detected among the 12280 students for the last 12 days of the semester, and the rolling 7-day average reached zero on the eighth day following the end of the two-dose administration period. Importantly, the effectiveness of BNT162b2 against shedding of SARS-CoV-2 RNA remains uncertain. 17, 18 Because viral loads have been found to be similar among asymptomatic, presymptomatic, and symptomatic infections, 1 wastewater surveillance offers a compelling opportunity to screen for SARS-CoV-2 RNA shedding that is agnostic to symptoms or care-seeking behavior. During and after the second dose of BNT162b2, SARS-CoV-2 RNA positivity in wastewater solids was significantly decreased, with 12 straight days of nondetection prior to the conclusion of the semester. BNT162b2 administration coincided with a significant decrease in wastewater positivity for SARS-CoV-2 RNA concurrent with a decreasing incidence of COVID-19 as observed via clinical testing. This is consistent with observations from clinical samples that found that breakthrough infections of vaccinated individuals were associated with lower virus loads, faster clearance, and the absence of culturable virus. 44 Because of the observational study design, the effects of secular trends on COVID-19 cases on campus, such as changes in campus activity due to reading days and final exams, changes in Environmental Science & Technology Letters pubs.acs.org/journal/estlcu Letter D COVID-19 incidence among the community outside the university, and changes in behavior associated with weather, could not be assessed. Importantly, during the study period, the delta variant (B.1.617.2) did not represent a notable proportion of COVID-19 cases in the study area, and thus, the findings should not be extrapolated to this variant of concern. Nonetheless, for the strains circulating on the ND campus at the time of the study, the observations suggest BNT162b2 may be effective against not only symptomatic COVID-19 but also SARS-CoV-2 RNA shedding among the student population.

■ ASSOCIATED CONTENT * sı Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.estlett.1c00519. Detailed procedure for nucleic acid extraction; detailed procedure for RT-ddPCR; RT-ddPCR assays (Table  S1 ); digital MIQE checklist (Table S2) ; SARS-CoV-2 copy number per gram calculation equation (Table S3) ; positive and negative RT-ddPCR examples (Table S4) ; partition volume, number, and copy number per partition summary statistics (Table S5) ; BRSV recovery efficiency ( Figure S1 ); Hep G inhibition assessment ( Figure S2 ); daily COVID-19 clinical test number ( Figure S3 ); N1 copy number per gram and COVID-19 positivity ( Figure S4 ); recovery-corrected N1 copy number per gram and COVID-19 cases ( Figure S5 ); recovery-corrected N1 copy number per gram and COVID-19 positivity ( Figure S6 ); PMMoV-normalized N1 copy number per gram and COVID-19 cases ( Figure  S7 ); PMMoV-normalized N1 copy number per gram and COVID-19 positivity ( Figure S8 ); PMMoV copy number per gram, wastewater solids wet mass, and recovery ( Figure S9 ); and daily wastewater flow ( Figure  S10) ■ REFERENCES

Suppression of a SARS-CoV-2 Outbreak in the Italian Municipality of Vo'

Detection of SARS-CoV-2 in Fecal Samples From Patients With Asymptomatic and Mild COVID-19 in Korea

SARS-CoV-2, SARS-CoV, and MERS-CoV Viral Load Dynamics, Duration of Viral Shedding, and Infectiousness: A Systematic Review and Meta-Analysis

Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2

Urinary Viral Shedding of COVID-19 and Its Clinical Associations: A Systematic Review and Meta-Analysis of Observational Studies

Wastewater-Based Epidemiology: Global Collaborative to Maximize Contributions in the Fight Against COVID-19

Show Us the Data: Global COVID-19 Wastewater Monitoring Efforts, Equity, and Gaps

COVID-19 Surveillance in Southeastern Virginia Using Wastewater-Based Epidemiology

SARS-CoV-2 Titers in Wastewater Are Higher than Expected from Clinically Confirmed Cases

Quantitative Analysis of SARS-CoV-2 RNA from Wastewater Solids in Communities with Low COVID-19 Incidence and Prevalence

Measurement of SARS-CoV-2 RNA in Wastewater Tracks Community Infection Dynamics

Catching a Resurgence: Increase in SARS-CoV-2 Viral RNA Identified in Wastewater 48 h before COVID-19 Clinical Tests and 96 h before Hospitalizations

Presence of SARS-Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the Early Stage of the Environmental Science & Technology Letters pubs.acs.org/journal/estlcu Letter Epidemic in The Netherlands

Making waves: Plausible lead time for wastewater based epidemiology as an early warning system for COVID-19

Wastewater-Based Estimation of the Effective Reproduction Number of SARS-CoV-2

Wastewater Monitoring Outperforms Case Numbers as a Tool to Track COVID-19 Incidence Dynamics When Test Positivity Rates Are High

The Advisory Committee on Immunization Practices' Interim Recommendation for

Vaccine  United States

Partitioning, and Recovery of Enveloped Viruses in Untreated Municipal Wastewater

SARS-CoV-2 RNA in Wastewater Settled Solids Is Associated with COVID-19 Cases in a Large Urban Sewershed

Scaling of SARS-CoV-2 RNA in Settled Solids from Multiple Wastewater Treatment Plants to Compare Incidence Rates of Laboratory-Confirmed COVID-19 in Their Sewersheds

COVID-19 Containment on a College Campus via Wastewater-Based Epidemiology, Targeted Clinical Testing and an Intervention

Wastewater Surveillance for SARS-CoV-2 on College Campuses: Initial Efforts, Lessons Learned, and Research Needs

Inferring SARS-CoV-2 RNA Shedding into Wastewater Relative to

Within-Day Variability of SARS-CoV-2 RNA in Municipal Wastewater Influent During Periods of Varying

US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2

CrAssphage and Pepper Mild Mottle Virus as Viral Water Quality Monitoring Tools -Potential, Research Gaps, and Way Forward

RNA Viral Community in Human Feces: Prevalence of Plant Pathogenic Viruses

Occurrence of Pepper Mild Mottle Virus in Drinking Water Sources in Japan

On a Test of Whether One of Two Random Variables Is Stochastically Larger than the Other

The Spearman Correlation Formula

On the Interpretation of X 2 from Contingency Tables, and the Calculation of

Challenges in Measuring the Recovery of SARS-CoV-2 from Wastewater

Nir-Paz, R. BNT162b2MRNA Covid-19 Vaccine Effectiveness among Health Care Workers

Impact of Age, Ethnicity, Sex and Prior Infection Status on Immunogenicity Following a Single Dose of the BNT162b2MRNA COVID-19 Vaccine: Real-World Evidence from Healthcare Workers, Israel

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel  33

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on Covid-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

A Determining the Incidence of Asymptomatic SARS-CoV-2 among Early Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers before, during and after Vaccination